抗肺纤维化新药吡非尼酮

A new drug treating idiopathic pulmonary fibrosis:pirfenidone

特发性肺纤维化是由不明原因引起的疾病,目前还没有一种药物来有效治疗该疾病。吡非尼酮是一类吡啶类的小分子物质,通过抑制转化生长因子-β,改变胶原合成和累积,抑制细胞外基质增殖和表达,具有抗炎、抗氧化和抗纤维化的作用。在一系列的临床试验中,显示了吡非尼酮是潜在治疗特发性纤维化的药物,具有良好的应用前景。

Idopathic pulmonary fibrosis（IPF） is a disease caused by unknown reason.To date,there is no one drug to effectively treat the disease.Pirfenidone is an anti-inflammatory,anti-oxidant,and antifibrotic angent that inhibits transforming growth factor-β in vitro and changes collagen synthesis and accumulation,and inhibits proliferation and extracellular matrix expression.In a series of clinical trials,pirfenidone is a potential for the treatment of IPF.